Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Immune Regulation News
Immune Regulation News is an online resource covering research into the regulation, suppression, and modulation of the immune system.
Bispecific Antibody Takes a BiTE Out of B Cells in Rheumatoid Arthritis
[Nature] Amgen’s B-cell-depleting therapy blinatumomab (Blincyto) showed signs of efficacy in rheumatoid arthritis, found an academic-sponsored pilot trial of the CD19xCD3 bispecific T-cell engager (BiTE) in six patients with the autoimmune disease.
Valrubicin-Loaded Immunoliposomes for Specific Vesicle-Mediated Cell Death in the Treatment of Hematological Cancers
[Cell Death & Disease] Following the transplantation of human pediatric B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, or acute myeloid leukemia in immunodeficient NSG mice, investigators generated patient-derived xenograft models, which were treated with valrubicin-loaded immunoliposomes loaded with antibodies to target CD19, CD7 or CD33.
HDAC Inhibition Increases CXCL12 Secretion to Recruit Natural Killer Cells in Peripheral T Cell Lymphoma
[Cancer Research] Researchers found that high expression of histone deacetylase (HDAC)3 was associated with poor prognosis in peripheral T cell lymphoma. HDAC3 inhibition suppressed lymphoma growth in immunocompetent mice but not in immunodeficient mice.
LGR6 Frameshift Variant Abrogates Receptor Expression on Select Leukocyte Subsets and Associates With Viral Infections
[Blood] In neutrophils, monocytes, and natural killer cells from volunteers homozygous for this variant, investigators found a significant downregulation in the expression of leucine-rich repeat-containing G-protein-coupled receptor 6 (LGR6) when compared with controls without the variant.
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the first patient with systemic lupus erythematosus has been treated in the Phase I autoimmunity study of FT819, the company’s off-the-shelf, CD19-targeted chimeric antigen receptor T cell program.
THEMIS Promotes T Cell Development and Maintenance by Rising the Signaling Threshold of the Inhibitory Receptor BTLA
[Proceedings Of The National Academy Of Sciences Of The United States Of America] Investigators showed that the T cell lineage protein THEMIS operates as a rheostat which restrain the signaling capacity the inhibitory receptor B- and T-lymphocyte attenuator (BTLA).
Triune Nanomodulator Enables Exhausted Cytotoxic T Lymphocyte Rejuvenation for Cancer Epigenetic Immunotherapy
[ACS Nano] Scientists presented a well-designed triune nanomodulator, termed ROCA, which demonstrated robust capabilities in tumor epigenetic modulation and immune microenvironment reprogramming for cancer epigenetic immunotherapy.
The Immunoglobulin Superfamily Ligand B7H6 Subjects T Cell Responses to NK Cell Surveillance
[Science Immunology] By screening for mediators of natural killer (NK) cell recognition on T cells, researchers identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells.
The Immunoglobulin Superfamily Ligand B7H6 Subjects T Cell Responses to NK Cell Surveillance
[Science Immunology] By screening for mediators of natural killer (NK) cell recognition on T cells, investigators identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells.
Thymocyte Migration and Emigration
[Immunology Letters] Investigators review the contribution of the key factors mentioned above for the localization, migration and emigration of thymocytes.
Traverse Biotech Awarded Phase I SBIR Grant by the National Institute of Allergy and Infectious Diseases for Development of Innate Immune Stimulator
[Traverse Biotech, Inc. (PR Newswire)] Traverse Biotech, Inc. has been awarded a Phase I Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases, part of the NIH.
ABBV-319: A CD19-Targeting Glucocorticoid Receptor Modulator Antibody-Drug Conjugate Therapy for B Cell Malignancies
[Blood] ABBV-319 elicited potent glucocorticoid receptor modulator-driven anti-tumor activity against multiple malignant B cell lines in vitro as well as in cell line-derived xenografts and patient-derived xenografts in vivo.
For over a decade, Immune Regulation News has been keeping the scientific community up-to-date with the latest research and reviews related to immune regulation. Key research areas covered include the roles of regulatory T cells (Treg cells) in autoimmunity and self-reactivity, as well as immune response to disease, transplantation and cancer. We also provide vital updates on the latest jobs and upcoming events in the field of immunology.
